Perrigo Faces Class Action for Misleading Statements, Deadline January 16, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 hour ago0mins
- False Statement Allegations: Perrigo is accused of issuing materially false or misleading statements from February 27, 2023, to November 4, 2025, leading investors to misunderstand the company's financial health, which negatively impacted stock performance.
- Capital Expenditure Needs: The lawsuit claims that Perrigo's acquired infant formula business requires substantial capital and operational expenditures due to significant underinvestment in maintenance and operational improvements, exceeding the company's previously stated cost estimates, potentially affecting future profitability.
- Manufacturing Deficiencies: Significant deficiencies in the manufacturing facility for the infant formula business have been identified, resulting in overstated financial results and undermining investor confidence in the company's prospects.
- Investor Action Call: Shareholders are encouraged to register for the class action by January 16, 2026, to receive status updates throughout the case lifecycle, ensuring their rights are protected.
PRGO.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is 27.50 USD with a low forecast of 23.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 13.440
Low
23.00
Averages
27.50
High
32.00
Current: 13.440
Low
23.00
Averages
27.50
High
32.00
Canaccord
Buy
downgrade
$40 -> $20
2025-11-06
Reason
Canaccord
Price Target
$40 -> $20
2025-11-06
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Perrigo to $20 from $40 and keeps a Buy rating on the shares. The firm noted Q3 was a beat but sales were weak in light of OTC trends and lower nutrition sales due to velocities below expectations and lapping a period where infant formula benefited from selling into retailers due to the port strike last year.
JPMorgan
Overweight -> Neutral
downgrade
$32 -> $20
2025-11-06
Reason
JPMorgan
Price Target
$32 -> $20
2025-11-06
downgrade
Overweight -> Neutral
Reason
JPMorgan downgraded Perrigo to Neutral from Overweight with a price target of $20, down from $32, post the Q3 report. The firm sees increased uncertainty for the business in the near term and over the next 12 months. The recovery in Perrigo's infant formula business is slower than expected amid competitive pressure and its over-the-counter market trends are uncertain, the analyst tells investors in a research note. JPMorgan prefers to revisit shares when it gets more clarity on these dynamics.
Jefferies
Keith Devas
Hold
downgrade
$27 -> $23
2025-10-27
Reason
Jefferies
Keith Devas
Price Target
$27 -> $23
2025-10-27
downgrade
Hold
Reason
Jefferies analyst Keith Devas lowered the firm's price target on Perrigo to $23 from $27 and keeps a Hold rating on the shares. Macro headwinds continue to be felt more acutely in consumer health than other pockets of staples, says the analyst, who lowered targets and estimates across the firm's consumer health coverage into Q3 earnings reports from the group.
Canaccord
Susan Anderson
Buy
downgrade
$42 -> $40
2025-08-07
Reason
Canaccord
Susan Anderson
Price Target
$42 -> $40
2025-08-07
downgrade
Buy
Reason
Canaccord analyst Susan Anderson lowered the firm's price target on Perrigo to $40 from $42 and keeps a Buy rating on the shares. The firm updated its model following Q2 results where sales were down but management reiterated both top and bottom-line expectations which are achievable given the company's limited tariff exposure, opportunity to benefit from trade down, new contract wins in PL OTC, and continued strong European business.
See All Ratings
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the main allegations against Perrigo in the class action lawsuits?
How did Perrigo's underinvestment in the infant formula business impact investors?
How might Perrigo's stock price change if the lawsuits are successful?
What could be the long-term financial impact of these lawsuits on Perrigo?